How Does Ghrelin Work? Mechanism of Action, Per the Research

The short answer

Ghrelin is a 28-amino-acid peptide hormone secreted mainly by the stomach. Its best-characterised action is binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor expressed in the pituitary, hypothalamus, brainstem, vagal afferents and several peripheral tissues. A 2018 review of hunger and the gut described ghrelin as the principal circulating hormone that increases before meals and stimulates food intake, in contrast to the satiety-signalling peptides released after nutrient arrival in the intestine (PMID 29366626). A 2021 review of gastrointestinal hunger and satiety signalling placed ghrelin within a wider network of gut-derived peptides that converge on hypothalamic and brainstem circuits controlling appetite (PMID 34153172).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or peptide-related research. Nothing here describes how any substance should be used. For general background on the hormone itself, see the hub page at /learn/ghrelin/.

Step 1: Secretion and acylation

Ghrelin is produced in the stomach and released into the circulation, with levels described as rising in the fasted state and falling after eating; a 2018 review of hunger, ghrelin and the gut summarised this pre-prandial rise as one of the hormone's defining features (PMID 29366626). A key chemical step is acylation: the peptide carries a fatty-acid modification that reviews identify as necessary for binding GHS-R1a, while an unacylated form also circulates. A review of ghrelin-based approaches to metabolic disease discussed the acylated and unacylated forms, and the enzymatic machinery that produces them, as separate targets of pharmacological interest (PMID 32538716).

Ghrelin-expressing cells are not confined to the gastric fundus. A 2017 review examining ghrelin in relation to gastrointestinal stromal tumours discussed expression of ghrelin and its receptor in gastrointestinal tissue and the questions that raises about local signalling (PMID 28348480). That literature is observational and tissue-based; researchers described associations rather than demonstrated causation.

Step 2: The receptor target (GHS-R1a)

GHS-R1a is the receptor through which acyl-ghrelin is understood to act. It is a class A G-protein-coupled receptor, classically coupled to Gq/11, whose activation triggers phospholipase C, inositol trisphosphate and diacylglycerol production, and a rise in intracellular calcium. Reviews of the ghrelin system in the brain describe GHS-R1a expression in hypothalamic and hippocampal regions and discuss receptor-level signalling as the entry point for the hormone's central effects (PMID 36527939). A review of ghrelin-based therapy of metabolic diseases framed GHS-R1a agonism, antagonism and inverse agonism as distinct pharmacological strategies, which implies the receptor is treated in the literature as having measurable activity even without ligand (PMID 32538716).

Receptor-level modulation reported in preclinical work

Beyond the peptide itself, some preclinical work has examined compounds that change how the receptor responds. A 2014 patent-focused review reported that hesperidin, a citrus flavonoid, potentiated ghrelin signalling in experimental systems (PMID 25176345). That is non-clinical, exploratory work and should be read as in-vitro and animal pharmacology rather than as evidence of a human effect.

Step 3: Central circuits — where the signal lands

Hypothalamic AgRP/NPY neurons

The arcuate nucleus of the hypothalamus contains AgRP/NPY neurons that are consistently described as the principal central target for ghrelin's orexigenic action. A 2023 mouse study in Nature Metabolism reported that CaMK1D signalling within AgRP neurons promoted ghrelin-mediated food intake, identifying an intracellular kinase step downstream of receptor activation (PMID 37277610). The study was conducted in mice; researchers used genetic and neuronal-circuit tools that are not transferable to human physiology without further work.

A 2025 review of leptin and ghrelin in appetite regulation in obesity described the two hormones as opposing arms of a homeostatic system, with ghrelin signalling hunger and leptin signalling energy sufficiency, and discussed how that balance is altered in obesity (PMID 39983918).

Vagal and brainstem routes

Not all of ghrelin's central action is thought to depend on the hormone crossing into the brain. Reviews of gut-brain appetite signalling describe vagal afferent fibres as a conduit by which gastrointestinal peptide signals reach the brainstem and hypothalamus (PMID 34153172). The 2018 review of hunger and the gut similarly positioned ghrelin within a gut-to-brain communication system rather than as a purely endocrine signal acting at a single site (PMID 29366626).

Reward and motivation circuitry

A separate body of work addresses ghrelin's action outside homeostatic hunger. A 2013 review on ghrelin, reward and motivation described GHS-R1a signalling in mesolimbic dopamine pathways and its reported relationship to the motivational, as opposed to purely metabolic, drive to eat (PMID 23652396). Much of the evidence summarised there came from rodent behavioural models.

Step 4: Peripheral physiology described in the literature

Growth hormone release

Ghrelin was identified as the endogenous ligand of the growth hormone secretagogue receptor, and pituitary growth hormone release remains the action for which the receptor was originally named. Reviews of ghrelin-based therapy of metabolic diseases discuss growth-hormone-axis activation alongside the hormone's metabolic actions when considering what receptor-targeting agents would be expected to do (PMID 32538716).

Glucose metabolism

Two reviews in Peptides address the glucoregulatory side of the system. A 2011 review of ghrelin and glucose homeostasis summarised evidence that the ghrelin system influences insulin secretion and glucose handling, and discussed pancreatic islet expression of ghrelin and its receptor (PMID 21396419). A 2018 review of ghrelin regulation of glucose metabolism revisited the same question with a focus on the acylation enzyme, islet signalling and the conditions under which glucoregulatory effects were observed (PMID 29412824). Both reviews reported that findings varied with species, nutritional state and experimental model.

Cardiovascular signalling

A 2016 review in Current Hypertension Reports examined ghrelin and blood pressure regulation, discussing reported vascular and autonomic actions of the peptide and the receptor's presence in cardiovascular tissue (PMID 26781255). The authors framed this as an area of active investigation rather than settled physiology.

Central nervous system beyond appetite

A 2023 review of the ghrelin system in Alzheimer's disease discussed hippocampal GHS-R1a expression and proposed links between ghrelin signalling, synaptic function and cognition, while noting that the clinical relevance remains unestablished (PMID 36527939).

Established versus proposed mechanism

Adverse Events and Safety Signals: What Studies Report

The verified literature summarised on this page is mechanistic and review-based rather than safety-focused, so it does not supply an adverse-event profile. What it does contain are physiological reasons researchers watch particular systems. Reviews of ghrelin and glucose metabolism reported effects on insulin secretion and glucose handling, which is why glycaemic parameters feature in discussions of ghrelin-targeting pharmacology (PMID 29412824). A review of ghrelin and blood pressure regulation discussed cardiovascular actions of the peptide, placing haemodynamic measures in the same category of interest (PMID 26781255). A review of ghrelin in relation to gastrointestinal stromal tumours examined tissue-level associations in the gut, an area the authors treated as unresolved (PMID 28348480). None of these reviews reported a tolerability profile for any product, and none of this constitutes safety guidance.

What the mechanism literature does not establish

• Species translation. The clearest intracellular findings, including the AgRP-neuron kinase pathway, came from mouse work (PMID 37277610).
• Context dependence. Glucoregulatory findings varied with model and nutritional state, as the 2011 and 2018 reviews reported (PMID 21396419, PMID 29412824).
• Obesity alters the system. The 2025 leptin-and-ghrelin review described changes in appetite-hormone signalling in obesity, meaning mechanisms mapped in healthy models may not apply unchanged (PMID 39983918).
• Therapeutic translation is incomplete. A review of ghrelin-based therapy of metabolic diseases discussed the system as a drug target under development rather than as an established treatment pathway (PMID 32538716).

Summary of the pathway

1. Gastric cells secrete ghrelin, which is acylated to the receptor-active form (PMID 32538716).
2. Circulating acyl-ghrelin rises before meals and falls after eating (PMID 29366626).
3. It binds GHS-R1a in the pituitary, hypothalamus, brainstem and peripheral tissues (PMID 36527939).
4. Central signalling, including kinase cascades in AgRP neurons, increases feeding drive in rodents (PMID 37277610).
5. Parallel actions on reward circuitry, glucose handling and cardiovascular tissue have been reported with differing levels of certainty (PMID 23652396, PMID 21396419, PMID 26781255).

References

• The gastrointestinal tract in hunger and satiety signalling (United European Gastroenterology Journal, 2021)
• The role of leptin and ghrelin in the regulation of appetite in obesity (Peptides, 2025)
• Ghrelin system in Alzheimer's disease (Current Opinion in Neurobiology, 2023)
• Hunger, ghrelin and the gut (Brain Research, 2018)
• Ghrelin and gastrointestinal stromal tumors (World Journal of Gastroenterology, 2017)
• Ghrelin regulation of glucose metabolism (Peptides, 2018)
• Ghrelin, reward and motivation (Endocrine Development, 2013)
• CaMK1D signalling in AgRP neurons promotes ghrelin-mediated food intake (Nature Metabolism, 2023)
• Ghrelin and Blood Pressure Regulation (Current Hypertension Reports, 2016)
• Ghrelin and glucose homeostasis (Peptides, 2011)
• Hesperidin potentiates ghrelin signaling (Recent Patents on Food, Nutrition & Agriculture, 2014)
• Ghrelin Based Therapy of Metabolic Diseases (Current Medicinal Chemistry, 2021)